VR 2076

Drug Profile

VR 2076

Alternative Names: ICS/LABA/LAMA inhaled triple therapy - Vectura; LABA/LAMA/ICS inhaled triple therapy- Vectura; SKP 2076; VR2076

Latest Information Update: 29 Dec 2016

Price : $50

At a glance

  • Originator SkyePharma PLC
  • Developer Mundipharma International; Vectura
  • Class Glucocorticoids; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Immunosuppressants; Muscarinic receptor antagonists; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Asthma

Most Recent Events

  • 23 Dec 2016 VR 2076 licensed to Mundipharma and an undisclosed US company for Asthma and Chronic obstructive pulmonary disease
  • 23 Dec 2016 Vectura announces intention to submit regulatory application in the EU in late 2022 or early 2023
  • 31 Mar 2015 Preclinical trials in Asthma in United Kingdom (Inhalation) prior to Mar 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top